News
CFDA announced drug clinical trial agency with qualification (No. 57, 2017)

CFDA announced drug clinical trial agency with qualification (No. 57, 2017)

On May 16th, 2017, CFDA announced drug clinical trial agency with qualification (No.7), No. 57, 2017). It is pointed out in the announcement that according to Drug Control Law of P.R.C. and Measures of Drug Clinical Trial Agency Qualification Accreditation (on trial), after data review and on-site inspection, including International Hospital of Peking University, 149 medical agencies were recognized as drug clinical trial agencies, and granted them with “ Certificate of Drug Clinical Trial Agency”.

23

2017

/

05

Ministry of Science and Technology print and distribute biotechnology innovative plan of “the 13th five year plan”

Ministry of Science and Technology print and distribute biotechnology innovative plan of “the 13th five year plan”

On May 10th, 2017, Ministry of Science and Technology published news on official website that for accelerating biotechnology and its industrial development, the biotechnology innovative plan of “the 13th five year plan” is formulated. (Hereinafter referred to as “the Plan”)

19

2017

/

05

ProteLight Signed at Jianying Economic and Trade Fair

ProteLight Signed at Jianying Economic and Trade Fair

On September 20th, Jiangyin Hi-Tech district government hold a conference with theme of constructing a national self-innovative demonstration area in South Jiangsu. Thirteen key and major projects that with large investment scale, high industrial level, and strong industry-driven singed on the conference. As a major project, ProteLight signed there, and President, Mr. YunChen made a speech on the conference.

26

2016

/

09

CCTV News reported ProteLight

CCTV News reported ProteLight

On August 9th, CCTV News reported Jiangyin Hi-Tech District and Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd., as a high technology and pharmaceutical corporation, ProteLight develops well in the industrial environment of Jiangyin High-Tech District.

11

2016

/

08

Anti-infection 1.1 New Drug PL-5 is approved to be in Clinical Trial

Anti-infection 1.1 New Drug PL-5 is approved to be in Clinical Trial

On April 15th, CFDA announced on internet that anti-infection 1.1 new drug PL-5 of Jiangsu ProteLight Pharma was approved to be in clinical trial, which is the first antimicrobial peptide innovative drug in clinical trial in China. With characters of low toxicity, high efficiency and anti-drug resistant bacteria, PL-5 has a significant advantage of disinfecting “the super bacteria”, which is resistant to traditional antibiotics. Antimicrobial peptide PL-5 being in clinical trial can relieve the suffering of patients with skin infection.

19

2016

/

04

Our New Technology Got U.S. Invention Patent License

Our New Technology Got U.S. Invention Patent License

On March 1st, 2016, the patent “antimicrobial peptide and methods of preparation and use” which was independently developed by Jiangsu ProteLight got the authorization of the U.S. invention patent license officially (patent license NO.US9, 273, 095B2 ).

06

2015

/

11

Dr. Yuxin Chen and Dr. Hartmut Michel attended the roundtable conference with the theme of “2015 Wuxin Innovation and Entrepreneurship Week”

Dr. Yuxin Chen and Dr. Hartmut Michel attended the roundtable conference with the theme of “2015 Wuxin Innovation and Entrepreneurship Week”

On September 21st, 2015, Wuxi Municipal Committee and Wuxi Municipal People’s Government hold the roundtable conference with the theme of “2015 Wuxin Innovation and Entrepreneurship Week”, which aims to expand the international perspective for Wuxi industrial development. Jiangsu ProteLight ‘s President Dr. Yuxin Chen, and Chief technical consultant Dr. Hartmut Michel were invited to attend the meeting and made speech there.

24

2015

/

09

ProteLight’s PL-5 was listed in Priority Review Varieties

ProteLight’s PL-5 was listed in Priority Review Varieties

National Health and Family Planning Commission of the P.R.C. intend to accelerate the production process of Key innovative new drug manufacture projects, key science and technology projects. The special implementation management office of Key innovative new drug manufacture projects propose to recommend 17 drugs, including ProteLight’s PL-5 as priority review varieties on basis on experts selecting suggestions.

15

2015

/

09

< 123456 >